Blood biopsy test reads platelets to detect human lung cancer

August 14, 2017
A visualization of how a blood-based biopsy screens platelets for cancer-linked RNA. Credit: Best et al.

Researchers in the Netherlands have designed a different approach to the liquid biopsy. Rather than looking for evidence of cancer DNA or other biomarkers in the blood, their test (called thromboSeq) could diagnose non-small cell lung cancer with close to 90% accuracy by detecting tumor RNA absorbed by circulating platelets, also known as thrombocytes. Non-small cell lung cancers make up the majority of lung cancer cases. The research appears August 14 in the journal Cancer Cell.

"Ultimately, the aim of liquid biopsy-based cancer detection is to detect all cancers at once in an early stage; an all-in-one test," says first author Myron Best, a researcher at the department of Neurosurgery of the VU University Medical Center in Amsterdam and the Cancer Center Amsterdam. "ThromboSeq might not only provide diagnostics, but potentially any other tumor type as well, and may enable tumor-type stratification."

Platelets are short-lived blood cells known to form blood clots in response to injury. However, platelets also respond to a range of inflammatory events and cancer. Because platelet cells don't have a nucleus of their own, all RNA found in platelets either comes from megakaryocytes (the cells that form platelets in bone marrow) or from RNA the platelets absorbed while circulating in blood. Platelets in a cancer-free person will contain a different compilation of RNA than platelets that interacted with a tumor, known as tumor-educated platelets.

The researchers studied blood samples of more than 700 people, which included people diagnosed with late-stage non-small cell lung cancer, a smaller group with early stage cancer, and a with no known cancer. People with diseases such as multiple sclerosis, chronic pancreatitis, and coronary artery disease were included in the control group to make sure the algorithm was screening for cancer-specific RNA, and not RNA platelets generally encounter in inflammation or disease.

As it ran, the thromboSeq algorithm scanned the approximately 5,000 different RNA molecules found in platelets, continuously optimizing its panel of RNA genes, arriving at the few that indicate a cancerous tumor. Then, the researchers ran screening tests of the blood samples to see how accurately they could diagnose cancer.

The analysis was inspired by swarming behavior in nature. Birds, insects, and fish all swarm to optimize their numbers for a purpose—either in defense against predators or to search for food. "Birds continuously adjust their location in the swarm relative to each other, thereby increasing the flock's coverage and, thus, the efficiency of the food-searching process," Best says. "We applied this natural phenomenon to our algorithms, which make use of the complex RNA repertoire present in platelets."

The thromboSeq test could diagnose early-stage cancer with 81% accuracy and late-stage cancer with 88% accuracy. In a validation control group matched for age, smoking status, and blood storage time, the algorithm yielded an accuracy up to 91%. Best believes the technology is robust enough to begin clinical trials.

"Although the tumor-educated platelets test does not, so far, provide perfect predictions, it may complement alternative liquid biopsy bio-sources such as cell-free DNA, extracellular vesicles, circulating proteins, and circulating tumor as well as imaging modalities such as CT scans," Best says.

Best and colleagues plan to further optimize their algorithm with more samples and tests in people who are suspected to have lung cancer but are not yet diagnosed. "We also aim to further understand the biological mechanism responsible for education in the presence of ," he says.

Explore further: Cancer cells metastasize by hitching a ride on platelets

More information: Cancer Cell, Best et al.: "Swarm intelligence-enhanced detection of non-small cell lung cancer using tumor-educated platelets." http://www.cell.com/cancer-cell/fulltext/S1535-6108(17)30296-9 , DOI: 10.1016/j.ccell.2017.07.004

Related Stories

Cancer cells metastasize by hitching a ride on platelets

September 8, 2016
Metastasis of cancer cells to sites distant from the primary tumor is the leading cause of cancer-related death, and there is growing evidence that platelets aid the dissemination of cancer cells.

Tumor RNA in platelets may diagnose and classify cancer, identify treatment strategies

October 31, 2015
Analysis of tumor RNA carried in platelets - blood components best known for their role in clotting - may prove to be more useful than other "liquid biopsy" technologies for diagnosing cancer and determining its primary location ...

Blood sample new way of detecting cancer

November 12, 2015
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood. Using this new method for blood-based RNA tests of blood platelets, ...

Blood banks face seasonal shortages, new screening rules

December 23, 2016
(HealthDay)—There's typically a shortage of both blood and platelets during the holiday season. But, tighter testing for a rare complication of transfusions makes the need for platelets even more urgent, experts at UT Southwestern ...

Aspirin slows growth of colon, pancreatic tumor cells

December 15, 2016
Researchers from Oregon Health and Science University and Oregon State University have found that aspirin may slow the spread of some types of colon and pancreatic cancer cells. The paper is published in the American Journal ...

Platelets suppress T cell immunity against cancer

May 5, 2017
Blood platelets help disguise cancer from the immune system by suppressing T cells, report scientists at the Medical University of South Carolina (MUSC) in the May 5, 2017 issue of Science Immunology. In extensive preclinical ...

Recommended for you

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Brain powered: Increased physical activity among breast cancer survivors boosts cognition

September 19, 2017
It is estimated that up to 75 percent of breast cancer survivors experience problems with cognitive difficulties following treatments, perhaps lasting years. Currently, few science-based options are available to help. In ...

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.